Henry Schein Stock Forecast, Price & News

Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

Is Henry Schein a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Henry Schein stock.
View analyst ratings for Henry Schein or view top-rated stocks.

How has Henry Schein's stock been impacted by COVID-19 (Coronavirus)?

Henry Schein's stock was trading at $57.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSIC shares have increased by 26.4% and is now trading at $72.89.
View which stocks have been most impacted by COVID-19.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for Henry Schein.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) issued its earnings results on Tuesday, November, 2nd. The company reported $1.10 EPS for the quarter, beating analysts' consensus estimates of $0.94 by $0.16. The firm earned $3.18 billion during the quarter, compared to the consensus estimate of $2.94 billion. Henry Schein had a trailing twelve-month return on equity of 15.75% and a net margin of 5.12%. During the same period last year, the firm earned $1.03 EPS.
View Henry Schein's earnings history.

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Shares of Henry Schein split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein announced that its Board of Directors has authorized a share buyback program on Thursday, May 13th 2021, which allows the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company's leadership believes its shares are undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $4.270-$4.350 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.320. The company issued revenue guidance of -.

What price target have analysts set for HSIC?

3 equities research analysts have issued 12 month price targets for Henry Schein's stock. Their forecasts range from $95.00 to $98.00. On average, they expect Henry Schein's share price to reach $97.00 in the next twelve months. This suggests a possible upside of 33.1% from the stock's current price.
View analysts' price targets for Henry Schein or view top-rated stocks among Wall Street analysts.

Who are Henry Schein's key executives?

Henry Schein's management team includes the following people:

• Stanley M. Bergman, Chairman & Chief Executive Officer
• James P. Breslawski, Vice Chairman & President (LinkedIn Profile)
• Steven Paladino, Chief Financial Officer, Director & Executive VP
• Christopher Pendergast, Chief Technology Officer & Senior Vice President
• Gerald A. Benjamin, Director, Chief Administrative Officer & EVP

What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein CEO Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Henry Schein's key competitors?

Some companies that are related to Henry Schein include McKesson (MCK), AmerisourceBergen (ABC), Cardinal Health (CAH), Owens & Minor (OMI) and Patterson Companies (PDCO).
View all of HSIC's competitors.

What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by many different institutional and retail investors. Top institutional shareholders include Generation Investment Management LLP (9.53%), BlackRock Inc. (8.74%), Longview Partners Guernsey LTD (6.80%), Invesco Ltd. (3.33%), American Century Companies Inc. (2.28%) and Pendal Group Ltd (1.96%). Company insiders that own Henry Schein stock include Deborah Derby, Gerald A Benjamin, James P Breslawski, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein.

Which major investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Renaissance Technologies LLC, BlackRock Inc., Bank of New York Mellon Corp, Generation Investment Management LLP, Alliancebernstein L.P., Scout Investments Inc., and Assenagon Asset Management S.A.. Company insiders that have sold Henry Schein company stock in the last year include Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Steven Paladino, and Walter Siegel.
View insider buying and selling activity for Henry Schein or view top insider-selling stocks.

Which major investors are buying Henry Schein stock?

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Pendal Group Ltd, Macquarie Group Ltd., Point72 Asset Management L.P., American Century Companies Inc., Balyasny Asset Management LLC, Balyasny Asset Management LLC, Morgan Stanley, and Leith Wheeler Investment Counsel Ltd..
View insider buying and selling activity for Henry Schein or or view top insider-buying stocks.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $72.89.

How much money does Henry Schein make?

Henry Schein has a market capitalization of $10.11 billion and generates $10.12 billion in revenue each year. The company earns $403.79 million in net income (profit) each year or $4.41 on an earnings per share basis.

How many employees does Henry Schein have?

Henry Schein employs 19,000 workers across the globe.

Does Henry Schein have any subsidiaries?

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, Maddox Practice Group, Maravet, Marrodent, Medivet, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

When was Henry Schein founded?

Henry Schein was founded in 1932.

What is Henry Schein's official website?

The official website for Henry Schein is www.henryschein.com.

Where are Henry Schein's headquarters?

Henry Schein is headquartered at 135 DURYEA RD, MELVILLE NY, 11747.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500, via email at [email protected], or via fax at 631-843-5541.